Compare BridgeBio Pharma Inc (BBIO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Verisign, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.9 (market cap $16.46B), while Verisign, Inc. trades at $265.75 (market cap $24.47B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.21% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | VRSN | |
|---|---|---|
Market Cap | $16.46B | $24.47B |
Sector | Health | Technology |
52-Week High | $90.17 | $310.00 |
52-Week Low | $44.81 | $211.49 |
Enterprise Value | $18.02B | $25.70B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
VeriSign (VRSN) trades at $270.31, up 0.07% with a bullish technical outlook. The stock shows strong fundamentals with 2025 revenue of $1.66B, net income of $825.7M, and exceptional 49.96% net margin. Recent Q1 2026 earnings beat expectations at $2.34 EPS. Analyst consensus is bullish with 57% buy ratings and $327.67 price target, representing 21% upside potential. The company maintains its monopoly position in .com/.net domain registry with predictable revenue growth.
VRSN presents a compelling investment case with stable cash flows and dominant market position, though trading at premium valuations (P/E 29.87). Key risks include contract renewals, AI disruption potential, and high debt levels. The upcoming Q2 2026 earnings report on July 23 will be critical for validating growth trajectory. Current levels offer attractive entry for long-term investors seeking defensive tech exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
